{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:21:20Z","timestamp":1794385280884,"version":"4.9.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.009","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:47:27Z","timestamp":1653079647000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis"],"prefix":"10.1016","volume":"349","author":[{"given":"Michael B.","family":"Boffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib3","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-319-49674-0_13","article-title":"fibrin formation, structure and properties","volume":"82","author":"Weisel","year":"2017","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib6","doi-asserted-by":"crossref","first-page":"15777","DOI":"10.1021\/bi00048a023","article-title":"Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a)","volume":"34","author":"Gabel","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib7","first-page":"46","article-title":"The kringle domains of human plasminogen","volume":"212","author":"Castellino","year":"1997","journal-title":"Ciba Found. Symp."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/bi048156p","article-title":"Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10","volume":"44","author":"Belczewski","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib9","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1073\/pnas.86.10.3847","article-title":"Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin","volume":"86","author":"Harpel","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib10","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1074\/jbc.270.11.6227","article-title":"Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a)","volume":"270","author":"Ernst","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib11","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1074\/jbc.RA119.011251","article-title":"Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function","volume":"295","author":"Sandmark","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib12","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1021\/bi973186w","article-title":"Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100","volume":"37","author":"Gabel","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/339303a0","article-title":"Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis","volume":"339","author":"Hajjar","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/339301a0","article-title":"A potential basis for the thrombotic risks associated with lipoprotein(a)","volume":"339","author":"Miles","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib15","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/bi00068a021","article-title":"Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation","volume":"32","author":"Ezratty","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib16","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00015a028","article-title":"Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation","volume":"34","author":"Sangrar","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib17","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1021\/bi962433d","article-title":"The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface","volume":"36","author":"Sangrar","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib18","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2018.05.029","article-title":"Inhibition of pericellular plasminogen activation by apolipoprotein(a): roles of urokinase plasminogen activator receptor and integrins alphaMbeta2 and alphaVbeta3","volume":"275","author":"Romagnuolo","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1538-7836.2008.03183.x","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation","volume":"6","author":"Feric","year":"2008","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2018.07.002","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells","volume":"169","author":"Romagnuolo","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm0395-256","article-title":"Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis","volume":"1","author":"Palabrica","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.plipres.2017.09.001","article-title":"The renaissance of lipoprotein(a): brave new world for preventive cardiology?","volume":"68","author":"Ellis","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib28","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/ATVBAHA.108.169292","article-title":"Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area","volume":"28","author":"Klein","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.CIR.88.3.935","article-title":"Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction","volume":"88","author":"Moliterno","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1536\/jhj.45.397","article-title":"Relation between serum lipoprotein (a) and residual lesion stenosis of coronary artery after myocardial Infarction without reperfusion therapy","volume":"45","author":"Matsuda","year":"2004","journal-title":"Jpn. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/clc.20143","article-title":"Relationship between lipoprotein(a) and spontaneous recanalization of infarct-related arteries in the early phase of acute myocardial infarction","volume":"31","author":"Kim","year":"2008","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","article-title":"Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes","volume":"41","author":"Tsimikas","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/hrt.71.4.316","article-title":"Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction","volume":"71","author":"MBewu","year":"1994","journal-title":"Br. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0002-9149(91)90737-6","article-title":"Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction","volume":"68","author":"Tranchesi","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib36","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/0140-6736(90)92557-X","article-title":"Lack of association between raised serum Lp(a) concentration and unsuccessful thrombolysis after acute myocardial infarction","volume":"336","author":"Armstrong","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib37","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0002-9149(91)90464-V","article-title":"Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction","volume":"67","author":"von Hodenberg","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0167-5273(94)90265-8","article-title":"Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase: no prediction of efficacy but inverse correlation with plasminogen activation in non-patency","volume":"45","author":"Brugemann","year":"1994","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib39","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1160\/TH04-02-0097","article-title":"Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator","volume":"91","author":"Ribo","year":"2004","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ejim.2007.10.019","article-title":"Venous and arterial thrombosis: different sides of the same coin?","volume":"19","author":"Franchini","year":"2008","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib42","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib44","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib45","first-page":"34","article-title":"Mendelian randomization \u2013 principles and its usage in lipoprotein(a) research","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib46","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women","volume":"11","author":"Danik","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib48","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib49","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1111\/jth.15068","article-title":"Inherited and acquired thrombophilia in adults with retinal vascular occlusion: a systematic review and meta-analysis","volume":"18","author":"Romiti","year":"2020","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib50","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1055\/s-0041-1732803","article-title":"Role of increased lipoprotein (a) in retinal vein occlusion: a systematic review and meta-analysis","volume":"5","author":"Paciullo","year":"2021","journal-title":"TH Open"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/01.CIR.100.7.743","article-title":"Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood","volume":"100","author":"Nowak-Gottl","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib52","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V94.11.3678","article-title":"Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood","volume":"94","author":"Nowak-Gottl","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(02)11520-0","article-title":"Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study","volume":"360","author":"Strater","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2012.073833","article-title":"Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children","volume":"98","author":"Goldenberg","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib55","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","article-title":"Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies","volume":"121","author":"Kenet","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1538-7836.2008.03186.x","article-title":"Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model","volume":"7","author":"Kuijpers","year":"2009","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.ATV.0000193624.28251.83","article-title":"What does it take to make the perfect clot?","volume":"26","author":"Monroe","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib58","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/ATVBAHA.114.303315","article-title":"Factor XII regulates the pathological process of thrombus formation on ruptured plaques","volume":"34","author":"Kuijpers","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib59","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"Rand","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib60","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation","volume":"85","author":"Martinez","year":"2001","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/09537109876852","article-title":"Lipoprotein (a) reduces platelet aggregation via apo(a)-mediated decreases in thromboxane A(2)production","volume":"9","author":"Barre","year":"1998","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.thromres.2004.01.002","article-title":"Apolipoprotein (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP","volume":"112","author":"Barre","year":"2003","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.thromres.2006.04.013","article-title":"Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb\/IIIa) receptor","volume":"119","author":"Barre","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cardiores.2004.03.005","article-title":"Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase","volume":"63","author":"Tsironis","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib65","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1007\/s12325-020-01483-y","article-title":"Relation of high lipoprotein (a) concentrations to platelet reactivity in individuals with and without coronary artery disease","volume":"37","author":"Salsoso","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-021-02515-2","article-title":"Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity","volume":"53","author":"Kille","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib67","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib68","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clinbiochem.2004.09.011","article-title":"The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease","volume":"38","author":"Bilgen","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib69","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1538-7836.2005.01517.x","article-title":"Effects of high plasma lipoprotein (a) levels on tissue factor pathway inhibitor and the protein C pathway","volume":"3","author":"Di Nisio","year":"2005","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1096\/fj.05-4857fje","article-title":"Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin","volume":"20","author":"Sotiriou","year":"2006","journal-title":"Faseb. J."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib71","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/STROKEAHA.115.009528","article-title":"Altered fibrin clot properties in patients with cerebral venous sinus thrombosis: association with the risk of recurrence","volume":"46","author":"Siudut","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib72","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"Undas","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"Undas","year":"2006","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib74","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2009-05-222380","article-title":"Altered fibrin clot structure\/function in patients with idiopathic venous thromboembolism and in their relatives","volume":"114","author":"Undas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib75","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.thromres.2012.06.005","article-title":"Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform","volume":"130","author":"Undas","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11239-018-1769-0","article-title":"Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties","volume":"47","author":"Skuza","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib77","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib78","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1016\/S0021-9258(19)84439-3","article-title":"Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a)","volume":"261","author":"Fless","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib79","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2002-08-2527","article-title":"Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk","volume":"101","author":"Wolberg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib80","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib81","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2009.09.077","article-title":"The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles","volume":"209","author":"Arai","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib82","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.thromres.2014.01.024","article-title":"Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties","volume":"133","author":"Rowland","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib83","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/jth.13759","article-title":"Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)","volume":"15","author":"Scipione","year":"2017","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib84","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1373\/clinchem.2017.276931","article-title":"High lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a mendelian randomization study","volume":"63","author":"Langsted","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib85","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/ATVBAHA.107.140046","article-title":"Vascular functions of the plasminogen activation system","volume":"27","author":"Fay","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib86","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11883-020-00867-3","article-title":"Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis","volume":"22","author":"Moriarty","year":"2020","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib87","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/ATVBAHA.120.314514","article-title":"Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses","volume":"40","author":"Mackman","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib88","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"Muller","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/joim.13338","article-title":"Lipoprotein(a) and SARS-CoV-2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events","volume":"291","author":"Di Maio","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11239-021-02597-y","article-title":"The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury","volume":"53","author":"Lippi","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.atherosclerosis.2021.12.008","article-title":"Lipoprotein(a), venous thromboembolism and COVID-19: a pilot study","volume":"341","author":"Nurmohamed","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib92","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1161\/01.ATV.13.4.548","article-title":"Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a)","volume":"13","author":"Williams","year":"1993","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.009_bib93","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/01.CIR.96.5.1612","article-title":"Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo","volume":"96","author":"Biemond","year":"1997","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:51:02Z","timestamp":1758156662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":92,"alternative-id":["S0021915022001861"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}